Seeking Alpha

Oncolytics Biotech (ONCY) +35.3% premarket after announcing positive results from a mid-stage...

Oncolytics Biotech (ONCY) +35.3% premarket after announcing positive results from a mid-stage clinical trial examining the use of its lead product candidate Reolysin in helping shrink tumors. ONCY says 95% of patients with squamous cell carcinoma of the lung using Reolysin intravenously in combination with carboplatin and paclitaxel exhibited overall tumor shrinkage.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs